- Home
- CMMB vs NERV Comparison
CMMB vs NERV Comparison
Compare CMMB & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- NERV
- Stock Information
- Founded
- CMMB 2004
- NERV 2007
- Country
- CMMB Israel
- NERV United States
- Employees
- CMMB N/A
- NERV N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- NERV Health Care
- Exchange
- CMMB Nasdaq
- NERV Nasdaq
- Market Cap
- CMMB 13.8M
- NERV 14.6M
- IPO Year
- CMMB N/A
- NERV 2014
- Fundamental
- Price
- CMMB $2.54
- NERV $3.78
- Analyst Decision
- CMMB Strong Buy
- NERV Hold
- Analyst Count
- CMMB 2
- NERV 1
- Target Price
- CMMB $26.50
- NERV $4.00
- AVG Volume (30 Days)
- CMMB 80.5K
- NERV 101.0K
- Earning Date
- CMMB 11-20-2025
- NERV 11-05-2025
- Dividend Yield
- CMMB N/A
- NERV N/A
- EPS Growth
- CMMB N/A
- NERV N/A
- EPS
- CMMB N/A
- NERV N/A
- Revenue
- CMMB N/A
- NERV N/A
- Revenue This Year
- CMMB N/A
- NERV N/A
- Revenue Next Year
- CMMB N/A
- NERV N/A
- P/E Ratio
- CMMB N/A
- NERV N/A
- Revenue Growth
- CMMB N/A
- NERV N/A
- 52 Week Low
- CMMB $2.36
- NERV $1.15
- 52 Week High
- CMMB $9.84
- NERV $12.46
- Technical
- Relative Strength Index (RSI)
- CMMB 42.45
- NERV 49.13
- Support Level
- CMMB $2.36
- NERV $3.76
- Resistance Level
- CMMB $2.85
- NERV $4.42
- Average True Range (ATR)
- CMMB 0.20
- NERV 0.32
- MACD
- CMMB -0.02
- NERV -0.09
- Stochastic Oscillator
- CMMB 32.71
- NERV 25.93
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.